# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

> **NCT07321106** · PHASE1 · RECRUITING · sponsor: **Cartography Biosciences** · enrollment: 80 (estimated)

## Conditions studied

- Colorectal Cancer
- Colorectal Cancer (CRC)
- Colorectal (Colon or Rectal) Cancer
- CRC
- Metastatic Colon Cancer
- Colon Cancer
- Advanced Colorectal Cancer

## Interventions

- **BIOLOGICAL:** CBI-1214

## Key facts

- **NCT ID:** NCT07321106
- **Lead sponsor:** Cartography Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2029-04
- **Final completion:** 2029-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321106, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07321106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*